Measles Vector As a Multigene Delivery Platform Facilitating IPSC Reprogramming

Overview

Journal Gene Ther

Date 2019 Feb 6

PMID 30718755

Citations 12

Authors

Qi Wang

Alanna Vossen

Yasuhiro Ikeda

Patricia Devaux

Affiliations

Soon will be listed here.

Abstract

Induced pluripotent stem cells (iPSCs) provide a unique platform for individualized cell therapy approaches. Currently, episomal DNA, mRNA, and Sendai virus-based RNA reprogramming systems are widely used to generate iPSCs. However, they all rely on the use of multiple (three to six) components (vectors/plasmids/mRNAs) leading to the production of partially reprogrammed cells, reducing the efficiency of the systems. We produced a one-cycle measles virus (MV) vector by substituting the viral attachment protein gene with the green fluorescent protein (GFP) gene. Here, we present a highly efficient multi-transgene delivery system based on a vaccine strain of MV, a non-integrating RNA virus that has a long-standing safety record in humans. Introduction of the four reprogramming factors OCT4, SOX2, KLF4, and cMYC via a single, "one-cycle" MV vector efficiently reprogrammed human somatic cells into iPSCs, whereas MV vector genomes are rapidly eliminated in derived iPSCs. Our MV vector system offers a new reprogramming platform for genomic modification-free iPSCs amenable for clinical translation.

Citing Articles

Engineering single-cycle MeV vector for CRISPR-Cas9 gene editing.

Rallabandi R, Sharp B, Majerus S, Royster A, Hoffer S, Ikeda M Mol Ther Methods Clin Dev. 2024; 32(3):101290.

PMID: 39070290 PMC: 11283025. DOI: 10.1016/j.omtm.2024.101290.

An engineered ligand-responsive Csy4 endoribonuclease controls transgene expression from Sendai virus vectors.

Kishimoto T, Nishimura K, Morishita K, Fukuda A, Miyamae Y, Kumagai Y J Biol Eng. 2024; 18(1):9.

PMID: 38229076 PMC: 10790456. DOI: 10.1186/s13036-024-00404-9.

Viral Replicon Systems and Their Biosafety Aspects.

van der Meulen K, Smets G, Rudelsheim P Appl Biosaf. 2023; 28(2):102-122.

PMID: 37342518 PMC: 10278005. DOI: 10.1089/apb.2022.0037.

Viral Vector-Based Gene Therapy.

Li X, Le Y, Zhang Z, Nian X, Liu B, Yang X Int J Mol Sci. 2023; 24(9).

PMID: 37175441 PMC: 10177981. DOI: 10.3390/ijms24097736.

Advances in RNA Viral Vector Technology to Reprogram Somatic Cells: The Paramyxovirus Wave.

Sharp B, Rallabandi R, Devaux P Mol Diagn Ther. 2022; 26(4):353-367.

PMID: 35763161 DOI: 10.1007/s40291-022-00599-x.

References

Takahashi K, Yamanaka S . Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006; 126(4):663-76. DOI: 10.1016/j.cell.2006.07.024. View

Duprex W, McQuaid S, Hangartner L, Billeter M, Rima B . Observation of measles virus cell-to-cell spread in astrocytoma cells by using a green fluorescent protein-expressing recombinant virus. J Virol. 1999; 73(11):9568-75. PMC: 112991. DOI: 10.1128/JVI.73.11.9568-9575.1999. View

Billeter M, Naim H, Udem S . Reverse genetics of measles virus and resulting multivalent recombinant vaccines: applications of recombinant measles viruses. Curr Top Microbiol Immunol. 2009; 329:129-62. PMC: 7120638. DOI: 10.1007/978-3-540-70523-9_7. View

Shi Y, Inoue H, Wu J, Yamanaka S . Induced pluripotent stem cell technology: a decade of progress. Nat Rev Drug Discov. 2016; 16(2):115-130. PMC: 6416143. DOI: 10.1038/nrd.2016.245. View

Pera M . Stem cells: The dark side of induced pluripotency. Nature. 2011; 471(7336):46-7. DOI: 10.1038/471046a. View

Fusaki N, Ban H, Nishiyama A, Saeki K, Hasegawa M . Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome. Proc Jpn Acad Ser B Phys Biol Sci. 2009; 85(8):348-62. PMC: 3621571. DOI: 10.2183/pjab.85.348. View

El Khatib M, Ohmine S, Jacobus E, Tonne J, Morsy S, Holditch S . Tumor-Free Transplantation of Patient-Derived Induced Pluripotent Stem Cell Progeny for Customized Islet Regeneration. Stem Cells Transl Med. 2016; 5(5):694-702. PMC: 4835241. DOI: 10.5966/sctm.2015-0017. View

Bitzer M, Armeanu S, Lauer U, Neubert W . Sendai virus vectors as an emerging negative-strand RNA viral vector system. J Gene Med. 2003; 5(7):543-53. DOI: 10.1002/jgm.426. View

Yu J, Hu K, Smuga-Otto K, Tian S, Stewart R, Slukvin I . Human induced pluripotent stem cells free of vector and transgene sequences. Science. 2009; 324(5928):797-801. PMC: 2758053. DOI: 10.1126/science.1172482. View

10.

Fujie Y, Fusaki N, Katayama T, Hamasaki M, Soejima Y, Soga M . New type of Sendai virus vector provides transgene-free iPS cells derived from chimpanzee blood. PLoS One. 2014; 9(12):e113052. PMC: 4257541. DOI: 10.1371/journal.pone.0113052. View

11.

Hu C, Li L . Current reprogramming systems in regenerative medicine: from somatic cells to induced pluripotent stem cells. Regen Med. 2015; 11(1):105-32. DOI: 10.2217/rme.15.79. View

12.

Kimbrel E, Lanza R . Current status of pluripotent stem cells: moving the first therapies to the clinic. Nat Rev Drug Discov. 2015; 14(10):681-92. DOI: 10.1038/nrd4738. View

13.

Parks C, Lerch R, Walpita P, Wang H, Sidhu M, Udem S . Comparison of predicted amino acid sequences of measles virus strains in the Edmonston vaccine lineage. J Virol. 2001; 75(2):910-20. PMC: 113987. DOI: 10.1128/JVI.75.2.910-920.2001. View

14.

Cattaneo R, Rebmann G, Schmid A, Baczko K, Ter Meulen V, Billeter M . Altered transcription of a defective measles virus genome derived from a diseased human brain. EMBO J. 1987; 6(3):681-8. PMC: 553451. DOI: 10.1002/j.1460-2075.1987.tb04808.x. View

15.

del Valle J, Devaux P, Hodge G, Wegner N, McChesney M, Cattaneo R . A vectored measles virus induces hepatitis B surface antigen antibodies while protecting macaques against measles virus challenge. J Virol. 2007; 81(19):10597-605. PMC: 2045491. DOI: 10.1128/JVI.00923-07. View

16.

Pless R, Bentsi-Enchill A, Duclos P . Monitoring vaccine safety during measles mass immunization campaigns: clinical and programmatic issues. J Infect Dis. 2003; 187 Suppl 1:S291-8. DOI: 10.1086/368049. View

17.

Schlaeger T, Daheron L, Brickler T, Entwisle S, Chan K, Cianci A . A comparison of non-integrating reprogramming methods. Nat Biotechnol. 2014; 33(1):58-63. PMC: 4329913. DOI: 10.1038/nbt.3070. View

18.

Park A, Hong P, Won S, Thibault P, Vigant F, Oguntuyo K . Sendai virus, an RNA virus with no risk of genomic integration, delivers CRISPR/Cas9 for efficient gene editing. Mol Ther Methods Clin Dev. 2016; 3:16057. PMC: 4996130. DOI: 10.1038/mtm.2016.57. View

19.

Robinson S, Galanis E . Potential and clinical translation of oncolytic measles viruses. Expert Opin Biol Ther. 2017; 17(3):353-363. PMC: 5381660. DOI: 10.1080/14712598.2017.1288713. View

20.

Lin T, Ambasudhan R, Yuan X, Li W, Hilcove S, Abujarour R . A chemical platform for improved induction of human iPSCs. Nat Methods. 2009; 6(11):805-8. PMC: 3724527. DOI: 10.1038/nmeth.1393. View